Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

May 08, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming analyst and institutional investor meeting to be held on Thursday, May 14, 2015, from 4:30 to 6:30 PM Eastern Time in New York City.
Apr 23, 2015
Corporate Update Conference Call at 11 am ET Today Agenus to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well
Apr 08, 2015
SECANT® yeast display technology to provide speed and cost advantages Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative
Feb 26, 2015
Agenus to host conference call at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulators (CPMs), heat shock protein-based vaccines, and immune adjuvants, today announced its
Feb 25, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein-based vaccines, as well as immune adjuvants, today announced that the Company will present at the Cowen and Company 35 th
Feb 03, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and immune adjuvants, today announced that the Company will present at the 17 th  Annual BIO CEO &
Oct 31, 2014
Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a development pipeline of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its
Sep 02, 2014
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced that Garo Armen, PhD, Chief Executive Officer, and Robert Stein, MD, PhD,
Jul 24, 2014
Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its financial
Jul 24, 2014
GSK’s RTS,S is the world’s first malaria vaccine candidate to undergo regulatory review Agenus’ QS-21 Stimulon® is a component of RTS,S and in 16 additional vaccine candidates undergoing patient studies Submission triggered regulatory milestone payment; Agenus entitled to royalties on product sales
Jun 19, 2014
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced that Robert Stein, MD, PhD, the company’s Chief Scientific Officer, will present a company
Jun 16, 2014
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus, Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, announced that it has been selected for inclusion in the broad-market Russell 3000   Index and Russell